Business Wire

WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features

8.5.2025 16:00:00 CEST | Business Wire | Press Release

Share

WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508546933/en/

WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG

These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translating the body’s most vital signals into guidance that extends healthspan, not just lifespan.

“This isn’t just a product launch. It’s a new chapter for WHOOP and for our members,” said Will Ahmed, WHOOP Founder & CEO. “We’ve taken everything we’ve learned over the past decade and built a platform to help our members perform and live at their peak for longer. We’ve held nothing back.”

Imagery of WHOOP 5.0 and WHOOP MG here.

NEW HEALTH AND PERFORMANCE IN-APP FEATURES:

  • Healthspan with WHOOP Age1: Get insights and guidance on how your daily habits impact your long-term health with Healthspan - a powerful new way to quantify your physiological age and slow your Pace of Aging. Developed in partnership with Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, Healthspan uses nine different metrics linked to long-term health to calculate your WHOOP Age and Pace of Aging.
  • Heart Screener with ECG2: Your heart, in your hands. WHOOP now includes an FDA-cleared ECG feature that allows a reading to be taken anytime, from your wrist — and shared directly with a healthcare provider. The Heart Screener detects signs of Atrial Fibrillation (Afib)3, a leading cause of stroke, and provides Irregular Heart Rhythm Notifications4 (IHRN) for greater peace of mind.
  • Blood Pressure Insights5: A patent-pending technology that delivers daily blood pressure insights, right from your wrist. Get estimated systolic and diastolic readings, and learn about how blood pressure affects wellbeing and performance.
  • Women’s Hormonal Insights6: WHOOP goes beyond cycle tracking to deliver science-backed education and personalized insights on how hormonal shifts influence recovery, sleep, stress and performance. Whether you’re navigating menstruation, pregnancy, or perimenopause — WHOOP adapts with you.
  • Sleep Performance Update: Unlock better nights and better days. The reimagined Sleep Score delivers a more accurate reflection of sleep quality, helping members recover more effectively and show up stronger each day.
  • WHOOP Advanced Labs7: Join the waitlist for the next evolution in personalized health. Coming soon, WHOOP Advanced Labs will allow members to schedule blood tests and receive clinician reports that are integrated directly into the WHOOP app, creating a more comprehensive picture of your health — and giving you actionable steps to improve it.
  • Comprehensive Fitness Tracking: From daily steps and VO₂ Max to Muscular Strain during strength training and 145+ supported activities, members can now optimize fitness for both performance and long-term health outcomes.

HARDWARE, REIMAGINED FOR PERFORMANCE AND PRECISION:

  • Precision Sensors. Smaller Design. Greater Power: WHOOP 5.0 and MG pack more technology into a seven percent smaller form factor. Enhanced sensors capture data 26 times per second, while a redesigned processor delivers 10x more power efficiency — enabling richer insights without sacrificing battery life or comfort.
  • 14+ Day Battery Life. New Wireless PowerPack8: 14+ days per charge across WHOOP 5.0 and MG hardware. Now, members with their device alongside the new Wireless Powerpack have access to a full month of battery life.
  • Elevated Accessories: Complete the experience with a new line of WHOOP accessories — including the new LeatherLuxe, crafted from genuine Italian leather for our most premium look and feel yet.
  • 24/7 Wearability: WHOOP remains the only wearable that’s truly wearable — designed for 24/7 use across multiple locations on the body. Powered by WHOOP Body and AnyWear™ technology, our technical garments seamlessly integrate with your device to capture data with unmatched precision — no matter your sport, lifestyle or movement.
  • Medical-Grade ECG: Available exclusively on WHOOP MG, maintain peace of mind with medical-grade ECG readings you can do from the comfort of home. Simply place your thumb and index finger on the ECG-conductive clasp, and get a medical-grade reading in seconds.

CHOOSE YOUR EXPERIENCE:

To make these innovations even more accessible, WHOOP is also introducing three new membership tiers. These tiers empower WHOOP members to choose the hardware device, features and pricing that make the most sense for them:

  • WHOOP One: Professional-grade fitness insights at our best price at $199 per year
  • WHOOP Peak: Advanced health, fitness and longevity insights designed to help you perform at your peak, longer. Priced at $239 per year
  • WHOOP Life: The most powerful WHOOP ever, delivering medical-grade health and performance insights. Priced at $359 per year

See below for global pricing.

“WHOOP is a great tool. It's like a doctor on my wrist,” said Cristiano Ronaldo, Professional Soccer Player and WHOOP Global Ambassador and Investor. “It allows me to monitor my behavior easily, and shows me that being consistent and prioritizing your health is worth it. I’m happy to be part of this company, and the launch of the WHOOP 5.0 and MG.”

WHOOP 5.0 and MG are available to purchase now on WHOOP.com.

Global Pricing

CURRENCY

ONE

PEAK

LIFE

USD

199

239

359

CAD

259

349

529

EUR

199

264

399

GBP

169

229

349

AUD

299

419

629

NZD

359

489

739

AED

699

919

1379

SAR

799

1029

1549

QAR

699

879

1319

About WHOOP

WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP 5.0 and WHOOP MG offer groundbreaking health innovations, including cardiovascular health features; Healthspan which quantifies Pace of Aging and provides members with their WHOOP Age; and first-of-its-kind wearable Blood Pressure Insights. WHOOP is the perfect health companion for anyone looking to optimize their health and performance. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. WHOOP is available to ship in 56 markets worldwide and the WHOOP app is available in English, French, German, Italian and Spanish (Latin America). WHOOP can be purchased on Amazon across the U.S., U.K., and Australia, as well as Best Buy (U.S.) Dick’s Sporting Goods (U.S.), Flipkart (India) and Virgin Megastore (GCC), and more.

To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.

_________________________________

1This feature is not available for users under the age of 18.

2This feature is not intended for users with known arrhythmias other than AFib or users under 22 years old. It is not recommended for users with a cardiac pacemaker, ICDs or other implanted electronic devices. This is a medically regulated feature and is not currently available in every region.

3https://pubmed.ncbi.nlm.nih.gov/33516402/

4This feature is not intended for users with known atrial fibrillation or users under 22 years old. This is a medically regulated feature and is not currently available in every region.

5Blood Pressure Monitor is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.

6Menstrual Cycle Insights should not be used for birth control or fertility tracking. The ovulatory phase indicators are estimates only. Menstrual Cycle Insights is not a medical device and cannot diagnose or manage medical conditions. It does not provide medical advice. Always consult your doctor for health concerns and never delay or modify medical care based on its information.

7USA only at launch.

8Wireless PowerPack is offered with Peak & Life Memberships. Wired battery pack available on One.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508546933/en/

Contacts

Sophie Holt
Jack Taylor PR
whoop@jacktaylorpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye